Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in Renal Disease

ERCHIVES-Renal

Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in Renal Disease
ERCHIVES-Renal: Study Design

**ERCHIVES-Renal Study Design**

- **Design**: Retrospective observational cohort review in Veterans Administration system to determine the effectiveness and safety of HCV treatment in persons with renal disease using two regimens: (1) ledipasvir-sofosbuvir, with or without ribavirin, and (2) ombitasvir-paritaprevir-ritonavir and dasabuvir, with or without ribavirin.

- **Entry Criteria**
  - Chronic HCV genotype 1-6 (most with genotype 1)
  - Baseline chronic kidney disease (CKD stage 1-5 included)
  - Compensated cirrhosis allowed
  - Persons with HIV were excluded

- **End-Points**: Primary = SVR12, treatment completion, and safety
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in Renal Disease
ERCHIVES-Renal: Results

Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir in Chronic Kidney Disease

Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in Renal Disease ERCHIVES-Renal: Results

Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir in Chronic Kidney Disease

Persons (%) with SVR 12

<table>
<thead>
<tr>
<th>CKD Stage 1-2</th>
<th>CKD Stage 3</th>
<th>CKD Stage 4-5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir</td>
<td>98.5</td>
<td>96.0</td>
</tr>
<tr>
<td>Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + Ribavirin</td>
<td>96.9</td>
<td>95.3</td>
</tr>
</tbody>
</table>

Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in Renal Disease
ERCHIVES-Renal: Results

Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir in Chronic Kidney Disease

**Conclusions**: “Ledipasvir-sofosbuvir and Ombitasvir-paritaprevir-ritonavir plus dasabuvir achieved high SVR rates in chronic kidney disease population. Treatment completion rates were lower than expected. A decline in eGFR and development of anaemia were observed in a substantial proportion of persons, but the clinical implications remain unclear.”
This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

**Hepatitis C Online**
[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

**Hepatitis Web Study**

Funded by a grant from the Centers for Disease Control and Prevention.